Effect of Mannan Oligosaccharide (MOS) on growth, physiological and immune performance parameters of broiler chickens
DOI:
https://doi.org/10.31580/pjmls.v3i2.1379Keywords:
Mannan oligo saccharides, Newcastle disease, Hemagglutination inhibition (HI), SRBC, IgM, IgGAbstract
Mannan oligosaccharides (MOS) are obtained from the outer cell wall of Saccharomyces cerevisiae. These (MOS) are among widely searched class to be used as feed additives in broiler chicken diets. Supplementation of Mannan oligo saccharides (MOS) are judiciously valuable in getting better growth performance, boosting immunity and attaining better physiological conditions during rearing of broiler chickens due to its capability of attaining equilibrium between beneficial and harmful microflora in the digestive tract, which is essential for regular working of gastro-intestinal tract. This study was intended to find out the influence of MOS supplementation on growth parameters, boost in immune status and physiological performance parameters to be tested in broilers. Significantly improved (P<0.05) growth performance (average daily gain, body weight, and feed conversion ratio) was achieved by the supplementation of mannan oligo saccharides. Significant (P<0.05) improvement among the parameters of immunity (Relative lymphoid organ weights, hemagglutination inhibition (HI), sheep red blood cell (SRBC) antibody reaction against Newcastle disease (ND), (IgG) resistant mercaptoethanol-2 and (IgM) sensitive mercaptoethanol-2) in mannan oligo saccharides supplemented groups of broiler chickens was achieved for Newcastle disease virus (NDV). There was non-significant (P>0.05) difference among bursa, thymus and spleen weight. Effects of supplementing different concentration (0, 0.5, 1.0 and 1.5 grams/kg for 42 days) of MOS on different haematological (erythrocyte sedimentation rate, haemoglobin (Hb), red blood cells, white blood cells, platelets) and serum biochemical parameters (ALT, AST, protein, globulin, albumin, cholesterol urea and creatinine) and haemoglobin showed a non-significant difference (P>0.05) in all treatment groups.




